Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

Clin Cancer Res. 2022 Dec 15;28(24):5469. doi: 10.1158/1078-0432.CCR-22-3568.
No abstract available

Publication types

  • Published Erratum